Look Forward – Autumn 2026 – Issue 191
Thank you to our fabulous 5K a Day in May supporters who raised more than £8,000 this year.
Search results
Thank you to our fabulous 5K a Day in May supporters who raised more than £8,000 this year.
As Luxturna reaches the clinic and other gene-specific therapies for inherited retinal disease get closer to the end of the development pipeline, it is becoming ever more important that affected families can access a genetic diagnosis, potentially opening up choices around treatment and clinical trial participation.
Retina UK is delighted to announce that it has awarded three new research grants worth more than £870,000.
It’s not very often that we come across a researcher working on a project inspired by their own lived experience of a sight loss condition.
On a typical week in the stem cell lab there are many different experiments going on. Different people work on their individual projects, but we often collaborate to share ideas and help each other.
Researchers in the Netherlands are developing a “retina-on-a-chip” that mimics the key layers of the human retina, offering a powerful new way to study inherited retinal diseases (IRDs) and test potential treatments using human cells.
Researchers from Ghent University have published a study that has the potential to transform inherited retinal disease (IRD) treatment development.
Inherited retinal dystrophies (IRDs) are the leading cause of blindness in working-age people in the UK, and children as young as eighteen-months are regularly diagnosed.
High quality information on genetic testing and counselling for families affected by inherited sight loss is now available in one place thanks to the launch of an innovative new website, Unlock Genetics.
Thursday 8 October 2026, 7.00pm - 8.00pm - via Zoom - Please come and join us for our Autumn meeting where 'This is Your Day to Have Your Say', celebrating both World Sight Day and Retina UK Day.